Alkermes (ALKS) Other Non-Current Assets (2011 - 2026)
Alkermes' (ALKS) quarterly Other Non-Current Assets came in at $59.4 million in Q1 2026, up 223.14% year-on-year from $18.4 million in Q1 2025, and up 20.89% on a QoQ basis from $49.1 million in Q4 2025.
Alkermes (ALKS) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Other Non-Current Assets data on file, last reported at $59.4 million in Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 223.14% year-over-year to $59.4 million in Q1 2026; TTM through Mar 2026 was $59.4 million, a 223.14% increase from a year earlier, with the FY2025 full-year figure at $49.1 million, up 197.52% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $59.4 million, up from $49.1 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for ALKS reached as high as $59.4 million in Q1 2026 and fell as low as $10.7 million in Q1 2022.
- Historically, Other Non-Current Assets has averaged $19.3 million across 5 years, with a median of $14.9 million in 2023.
- Across the five-year window, Other Non-Current Assets sank 46.49% in 2022 and soared 223.14% in 2026, its largest moves.
- Year by year, Other Non-Current Assets stood at $14.7 million in 2022, then dropped by 21.58% to $11.5 million in 2023, then jumped by 43.24% to $16.5 million in 2024, then surged by 197.52% to $49.1 million in 2025, then climbed by 20.89% to $59.4 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $59.4 million in Q1 2026, $49.1 million in Q4 2025, and $19.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 59.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.36 Mn |
| Dec 31, 2025 | 49.10 Mn |
| Sep 30, 2025 | 19.66 Mn |
| Jun 30, 2025 | 19.91 Mn |
| Mar 31, 2025 | 18.37 Mn |
| Dec 31, 2024 | 16.50 Mn |
| Sep 30, 2024 | 16.80 Mn |
| Jun 30, 2024 | 16.30 Mn |
| Mar 31, 2024 | 11.52 Mn |
| Dec 31, 2023 | 11.52 Mn |
| Sep 30, 2023 | 11.29 Mn |
| Jun 30, 2023 | 14.54 Mn |
| Mar 31, 2023 | 14.91 Mn |
| Dec 31, 2022 | 14.69 Mn |
| Sep 30, 2022 | 10.98 Mn |
| Jun 30, 2022 | 11.57 Mn |
| Mar 31, 2022 | 10.66 Mn |
| Dec 31, 2021 | 27.46 Mn |
| Sep 30, 2021 | 16.77 Mn |
| Jun 30, 2021 | 17.40 Mn |